AR

Ankit Rathi

Active Director Director DIN 08027666
DIN 08027666 First appointment Jan 2018 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2018
Shareholding value •••• Premium profile

About Ankit Rathi

Data last updated:

Ankit Rathi is a Director at Othantic Pharmaceuticals Private Limited (since 2018). The company operates in Pharma. Othantic Pharmaceuticals Private Limited reported revenue of ₹1.84 Cr (FY 2025).

DIN 08027666
Primary Designation Director
Industry Pharma
First Appointment 09 Jan 2018
Oldest Company Age 8 yrs
Largest company Othantic Pharmaceuticals Private Limited · ₹1.84 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director09 Jan 20182018₹1.84 Cr (FY 2025)Active

Board colleagues of Ankit Rathi

Directorship timeline

Open interactive timeline →
Othantic Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Ankit Rathi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ankit Rathi

Ankit Rathi currently holds 1 directorship: Othantic Pharmaceuticals Private Limited (Director, since 09 Jan 2018, revenue ₹1.84 Cr (FY 2025)).

Ankit Rathi was first appointed on 09 Jan 2018 as Director at Othantic Pharmaceuticals Private Limited.

The current boards of Ankit Rathi's companies include Manglesh Rathi (Othantic Pharmaceuticals Private Limited), Tarun Kalyan Sarda (Othantic Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available